Baseline characteristics | Etanercept | Infliximab | Adalimumab | Combined |
Number of cases | 278 (43) | 296 (46) | 68 (11) | 642 |
Age, years* | 57 (11) | 58 (11) | 59 (12) | 57 (11) |
No. female | 223 (80) | 228 (77) | 51 (75) | 502 (78) |
Current smokers | 56 (20) | 51 (17) | 6 (9) | 113 (18) |
Ever smoked | 163 (59) | 168 (57) | 35 (51) | 366 (57) |
Disease duration, years* | 13 (9) | 15 (10) | 13 (10) | 14 (10) |
DAS28* | 6.7 (1) | 6.7 (1) | 6.5 (1) | 6.7 (1) |
HAQ* | 2 (0.6) | 2 (0.6) | 2 (0.5) | 2 (0.6) |
Concurrent DMARD(s) | 152 (55) | 277 (94) | 38 (56) | 467 (73) |
Concurrent steroids | 105 (38) | 135 (46) | 24 (35) | 264 (41) |
Previous biological | 21 (8) | 10 (3) | 3 (4) | 34 (5) |
*Values are mean (SD). All other values are n (%).
DAS28, 28-joint disease activity score; DMARD, disease-modifying antirheumatic drug; HAQ, Health Assessment Questionnaire.